Business Wire

Prosimo Announces General Availability of AWS Cloud WAN Integration

Share

Prosimo, the Application Experience Infrastructure company, today announced the general availability of its integration with AWS Cloud WAN. This comes on the heels of AWS announcing today the general availability of AWS Cloud WAN. AWS Cloud WAN customers can now deploy the Prosimo platform to build an elastic and scalable Full Stack Cloud Transit for cross-region connectivity and segmentation to simplify and reduce operational burdens, deliver better experiences and lower costs.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220712005998/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

AWS Cloud WAN customers can now deploy the Prosimo platform to build an elastic and scalable Full Stack Cloud Transit for cross-region connectivity and segmentation to simplify and reduce operational burdens, deliver better experiences and lower costs. (Graphic: Business Wire)

"With these new features and functionality on the AXI Platform, Prosimo will be ideally suited to meet our goals: enable modern infrastructure capabilities using newer AWS networking constructs such as Cloud WAN, built-in observability for applications, and remove as much complexity as possible,” said Kevin Paige, CISO, Flexport

Enterprises can now simplify how they build and manage connectivity of their disparate environments across AWS regions across the globe, on-premises data centers, colocation facilities, branch offices, and their distributed user base with the combination of AWS Cloud WAN and Prosimo:

  • Achieve fine-grained elastic segmentation – The global network policy in AWS is kept coarse-grained and straightforward by design to be easy to manage and does not change that frequently. Fine-grained policy-based segmentation and security is the requirement from the application teams, in addition to the network layer segmentation. Prosimo helps to build policies at the per user and per-application level, on top of global network segments from Cloud WAN.
  • Hassle-free connectivity from AWS to any cloud – Regardless of how customers approach the core network policy, they will seek to achieve similar hassle-free connectivity to any of their DCs, other cloud providers, and edge co-locations. Prosimo helps extend the same core network policy model with segmentation to any cloud, including on-prem locations.
  • Modern cloud / NetDevOps operational model – Internal constituents such as modern cloud or NetDevOps teams will achieve a higher change frequency. With Prosimo’s APIs and Terraform modules, enterprise teams can integrate with their CI/CD flows for more agile development and deployment models while adhering to security and compliance guardrails and maintaining operational consistency.

Related Link: Sign up directly from the AWS Marketplace .

AWS Cloud WAN furthers Autonomous Multi-cloud Networking Solution

To ensure their multi-cloud environment is consistent, and easy-to-use, enterprises need to build an intelligent fabric that automatically connects applications, services, and networks across cloud infrastructures based on pre-set operations, security, and performance requirements. This requires first solving cloud connectivity issues then building an app transit layer that is autonomous and machine-driven to mitigate inherent complexity. Combining Network Transit and App Transit in a single architecture that simplifies and, most importantly, automates multi-cloud networking.

One Platform to Rule Them All

The combined network transit and app-to-app transit create a Full Stack Cloud Transit built on cloud-native constructs to take advantage of AWS’s global presence including AWS Cloud WAN. This gives enterprises a simpler connectivity model to migrate and connect their brownfield cloud deployments to deliver consistent, reliable, and secure Zero Trust-driven networks to support business-critical and latency-sensitive applications for users in any location.

“Our deepening relationship with AWS reflects the growing interest from AWS customers for simplified cloud networking solutions beyond just connectivity,” said Mani Ganesan, Head of Products, Prosimo. “AWS Cloud WAN and Prosimo offer a seamless and tightly integrated autonomous cloud networking solution as enterprises continue their enterprise cloud journeys and modernize their infrastructure.”

Resources

Connect with Prosimo

About Prosimo:

Prosimo delivers simplified multi-cloud infrastructure for distributed enterprise cloud journeys. Companies innovate faster and remain in control with the Prosimo integrated stack. This stack combines cloud networking, performance, security, observability, and cost management—all powered by data insights and machine learning models with autonomous cloud networking to reduce complexity and risk. Cloud-forward enterprises, including F100, have adopted Prosimo to successfully roll out revenue-generating applications, improve operational efficiency, and accelerate positive business outcomes. Prosimo is venture-backed by marquee investors such as General Catalyst and WRVI Capital. For more information, visit https://www.prosimo.io.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Press and Analyst Contact:
Matt Stubbs
Outside Labs for Prosimo
(801) 703-6626
press@prosimo.io

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 11:00:00 EET | Press release

Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in

Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 11:00:00 EET | Press release

Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration

Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 11:00:00 EET | Press release

Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo

Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 10:00:00 EET | Press release

Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of

Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 09:44:00 EET | Press release

Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye